News

2016 News Releases

Keyword Search
 
2017 | 2016
DateTitle 
12/19/16Aralez Added To The NASDAQ Biotechnology Index
MISSISSAUGA, Ontario, Dec. 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective as of the opening of trading on Monday, December 19, 2016. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Ben... 
Printer Friendly Version
12/19/16Aralez Announces Commercial Launch Of BLEXTEN™ In Canada
MISSISSAUGA, Ontario, Dec. 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company) today announced the commercial launch of BLEXTEN™ (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives) in Canada. BLEXTEN will be distributed in Canada by Tribute Pharmaceuticals Canada Inc. (Tribute), a subsidiary of the Company. "We are pleased to ... 
Printer Friendly Version
12/15/16Aralez Provides Update on PBM Formulary Status for Yosprala
-Secures Formulary Status with CVS Caremark for YOSPRALA™ MISSISSAUGA, Ontario, Dec. 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that it has entered into a rebate agreement with CaremarkPCS Health (also known as CVS Caremark), which secures formulary status for YOSPRALA™, the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and a proton pump inhibitor, omeprazole, in the United State... 
Printer Friendly Version
11/30/16Aralez to Participate at Two Upcoming Healthcare Conferences
MISSISSAUGA, Ontario, Nov. 30, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that Adrian Adams, Chief Executive Officer, will participate in the following healthcare conferences: Guggenheim's One-on-One Healthcare Conference in Boston on Tuesday, December 13, 2016 BMO Healthcare Conference in New York on Wednesday, December 14, 2016 at 11:00 a.m. A live webcast and audio archive for the BMO even... 
Printer Friendly Version
11/14/16New Post-Hoc Analysis Supports YOSPRALA™ Efficacy And Safety In Previous Heart Attack Patients Who Need Daily Aspirin Therapy To Prevent A Second Cardiovascular Event
-Shows Significant Reduction in Gastrointestinal Side Effects with Use of Fixed-Dose Combination of Aspirin and Proton Pump Inhibitor- MISSISSAUGA, Ontario, Nov. 14, 2016 /PRNewswire/ --Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced new data for YOSPRALA™, a recently FDA-approved prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), demonstrated significantly lower rates of ... 
Printer Friendly Version
11/07/16Aralez Reports Third Quarter 2016 Financial Results
-Completed Acquisitions of ZONTIVITY®; Toprol-XL® and its Authorized Generic- -Received U.S. Food and Drug Administration Approval and Launched YOSPRALA™- -Provides Improved 2016 Full Year Guidance- MISSISSAUGA, Ontario, Nov. 7, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced financial results for the third quarter ended September 30, 2016. The Company also highlighted certain corporate and commercial updates. Al... 
Printer Friendly Version
11/02/16Aralez to Present at the Jefferies London Healthcare Conference
MISSISSAUGA, Ontario, Nov. 2, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Jefferies London Healthcare Conference to be held November 16-17, 2016. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 4:40 p.m. local time on Wednesday, November 16, 2016. A live webcast and audio archive for the event may be accessed from the In... 
Printer Friendly Version
10/31/16Aralez Completes Acquisition Of Toprol-XL® And Its Authorized Generic From AstraZeneca
-Aralez Enters into Long-term Supply Agreement with AstraZeneca- -Transaction Expected to be EBITDA Accretive and to Move Profitability Forward to 2017 on an Adjusted Basis- MISSISSAUGA, Ontario, Oct. 31, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its subsidiary, Aralez Pharmaceuticals Trading DAC (Aralez Ireland), has completed its acquisition of the U.S. rights to Toprol-XL® (metoprolol s... 
Printer Friendly Version
10/24/16Aralez To Announce Third Quarter 2016 Results On November 7, 2016
-Executive Management to Host Conference Call on November 7, 2016 at 11:00 a.m. ET- MISSISSAUGA, Ontario, Oct. 24, 2016 /PRNewswire/ --Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 11:00 a.m. ET on such date to discuss the financial result... 
Printer Friendly Version
10/04/16Aralez to Acquire From AstraZeneca U.S. Rights to Beta Blocker Toprol-XL®
-On an Adjusted EBITDA Basis, Transaction Expected to be EBITDA Accretive and to Move Profitability Forward to 2017- -Company to Host Conference Call on October 4, 2016 at 8:30 a.m. ET-MISSISSAUGA, Ontario – October 4, 2016 – Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced it will acquire the U.S. rights to Toprol-XL® (metoprolol succinate) and its Authorized Generic (AG) pursuant to an agreement entered into between Astr... 
Printer Friendly Version
10/03/16Aralez Announces U.S. Commercial Launch Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
MISSISSAUGA, Ontario, Oct. 3, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, announced today the availability of once-daily YOSPRALA™, the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), in the U.S. YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of ... 
Printer Friendly Version
09/15/16Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
-Aralez Sales Force Will Be Expanded by 85 to 110 Sales Representatives by Launch- -YOSPRALA U.S. Commercial Launch Planned for First Week of October- -Company to Host Conference Call Today at 11:00 a.m. ET- MISSISSAUGA, Ontario, Sept. 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved once-daily YOSPRALA™, the only prescription fixed... 
Printer Friendly Version
09/07/16Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
-Acquired ZONTIVITY® in the U.S. and Canada- -Long-range market exclusivity through regulatory exclusivity and intellectual property protection- MISSISSAUGA, Ontario, Sept. 7, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that it acquired the U.S. and Canadian rights to ZONTIVITY® (vorapaxar), pursuant to an asset purchase agreement entered into between Merck, known as MSD outside the United States... 
Printer Friendly Version
08/09/16Aralez Reports Second Quarter 2016 Financial Results
MISSISSAUGA, Ontario, Aug. 9, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced financial results for the second quarter ended June 30, 2016. The Company also highlighted certain corporate, commercial, and regulatory updates. All figures are in U.S. dollars. Corporate Updates: On April 25, 2016, the Company announced Health Canada's approval of BLEXTEN™ (bilastine 20 mg oral tablet) for the treatment of the symptoms of... 
Printer Friendly Version
07/26/16Aralez To Announce Second Quarter 2016 Results On August 9, 2016
-Executive Management to Host Conference Call on August 9, 2016 at 11:00 a.m. ET- MISSISSAUGA, Ontario, July 26, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its second quarter 2016 financial results on Tuesday, August 9, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 11:00 a.m. ET on such date to discuss the financial resul... 
Printer Friendly Version
07/06/16Aralez To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
MISSISSAUGA, Ontario, July 6, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that executive management will participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference to be held July 12-13, 2016 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 3:30 p.m. local time on Wednesday, July 13, 2016. A live webcast and audio archive for the ev... 
Printer Friendly Version
06/16/16Aralez Announces Voting Results From 2016 Annual General Meeting Of Shareholders
MISSISSAUGA, Ontario, June 16, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced the results of the matters voted upon at the Company's 2016 annual general meeting (the "Meeting") of shareholders (the "Shareholders") held earlier today, which included the election of directors, as described below.  The total number of common shares of the Company ("Common Shares") represented by Shareholders present in person or represente... 
Printer Friendly Version
06/02/16Aralez To Present At The Jefferies Healthcare Conference
MISSISSAUGA, Ontario, June 2, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the executive management will participate in the Jefferies Healthcare Conference to be held June 7-10, 2016 in New York. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 9:30 a.m. local time on Thursday, June 9, 2016. A live webcast and audio archive for the event may be accessed from the Investors... 
Printer Friendly Version
05/16/16Aralez Distributes Meeting Materials For 2016 Annual General Meeting Of Shareholders
MILTON, Ontario, May 16, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced that it has distributed its proxy statement and related meeting materials ("Meeting Materials") in connection with its upcoming 2016 Annual General Meeting of Shareholders (the "Annual Meeting") to be held on Thursday, June 16, 2016 at 1:00 p.m. ET at the offices of Stikeman Elliott LLP, 5300 Commerce Court West, 199 Bay Street, Toronto, ON, Canada M5L ... 
Printer Friendly Version
05/10/16Aralez Reports First Quarter 2016 Financial Results
-First Quarter 2016 Includes the Operations of Tribute from February 5, 2016 through March 31, 2016- MILTON, Ontario, May 10, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced financial results for the first quarter ended March 31, 2016. The Company also highlighted important corporate, commercial, and regulatory updates. All figures are in U.S. dollars. Corporate Updates: On April 25, 2016, the Company announc... 
Printer Friendly Version
04/28/16Aralez To Present At The Deutsche Bank 41st Annual Healthcare Conference
MILTON, Ontario, April 28, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its executive management will participate in the Deutsche Bank 41st Annual Healthcare Conference to be held May 4-5, 2016 in Boston. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:30 p.m. local time on Thursday, May 5, 2016. A live webcast and audio archive for the event may be accessed from ... 
Printer Friendly Version
04/28/16Aralez To Announce First Quarter 2016 Results On May 10, 2016
-Executive Management to Host Conference Call on May 10, 2016 at 8:30 a.m. ET- MILTON, Ontario, April 28, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ)(TSX: ARZ), today announced that it will report its 2016 first quarter financial results on Tuesday, May 10, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and recent highlights... 
Printer Friendly Version
04/25/16Aralez To Present At The Bloom Burton & Co. Healthcare Investor Conference
MILTON, Ontario, April 25, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that its executive management will participate in the Bloom Burton & Co. Healthcare Investor Conference to be held May 2-3, 2016 in Toronto. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 11:30 a.m. local time on Monday, May 2, 2016. A live webcast and audio archive for the event may be accessed... 
Printer Friendly Version
04/25/16Aralez Receives Health Canada Approval For BLEXTEN™
MILTON,  Ontario, April 25, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced the Health Canada approval of BLEXTEN™ (bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives). The approval was granted to Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez formed under... 
Printer Friendly Version
04/20/16Aralez Announces Several Corporate Updates
-The Company Reports Additional Steps Taken to Support the Submission of the YOSPRALA™ New Drug Application- -The Company Announces the Promotional Launch of Fibricor® in the United States- MILTON, Ontario, April 20, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced several corporate updates. The Company reported additional details regarding the steps that have been taken t... 
Printer Friendly Version
04/19/16Aralez Appoints James L. Hall As General Manager Of Canadian Business
MILTON, Ontario, April 19, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that James L. Hall will be appointed to General Manager of its wholly owned subsidiary, Tribute Pharmaceuticals Canada Inc., effective May 16, 2016. "We are pleased to have Jim assume the newly created position of General Manager, Canada," said Adrian Adams, Chief Executive Officer of Aralez. "His valuabl... 
Printer Friendly Version
04/04/16Aralez to Open Toronto Stock Exchange on April 5, 2016
MILTON, Ontario – April 4, 2016 – Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that the Company will open the Toronto Stock Exchange at 9:30 a.m. ET on Tuesday, April 5, 2016. Chief Executive Officer, Adrian Adams, will perform the honorary market open ceremony that will be held at 9:30 a.m. ET. A live webcast will be available at: https://www.youtube.com/watch?v=v1Q89w3wnyw. Members of the Aralez Board of Directors, Ex... 
Printer Friendly Version
03/28/16Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™
MILTON, Ontario, March 28, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has acknowledged acceptance of the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. The FDA Prescription D... 
Printer Friendly Version
03/15/16Aralez Reports Fourth Quarter And Full-Year 2015 Results
- Announced Today the Resubmission to the FDA of the NDA for YOSPRALA™- - Expects 2016 Net Revenues to be in a Range of $48 Million to $58 Million- MILTON, Ontario, March 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), today announced results for the fourth quarter and full-year ended December 31, 2015. The Company also highlighted important corporate, commercial, and regulatory updates. All figures are in U.S. dollars. Cor... 
Printer Friendly Version
03/15/16Aralez resubmits to FDA New Drug Application for YOSPRALA
MILTON, Ontario, March 15, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA™ (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. Secondary prevention with a... 
Printer Friendly Version
03/01/16Aralez To Announce Fourth Quarter And Full-Year 2015 Results On March 15, 2016
-Executive Management to Host Conference Call on March 15, 2016 at 8:30 a.m. ET- MILTON, Ontario, March 1, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), today announced that it will report its 2015 fourth quarter and full-year financial results on Tuesday, March 15, 2016, before the opening of the U.S. financial markets. Following the announcement, executive management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial r... 
Printer Friendly Version
02/22/16Aralez To Present At The Cowen and Company 36th Annual Healthcare Conference
MILTON, Ontario, Feb. 22, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced that members of its executive management will participate in the Cowen and Company 36th Annual Healthcare Conference to be held March 7-9, 2016 in Boston. Adrian Adams, Chief Executive Officer, will provide an overview of the Company at 1:20 p.m. local time on Monday, March 7, 2016. A live webcast and audio archive for the event may b... 
Printer Friendly Version
02/12/16Aralez to Ring Closing Bell at Nasdaq on February 16, 2016
MILTON, Ontario, Feb. 12, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 16, 2016 to celebrate the formation of Aralez. Chief Executive Officer, Adrian Adams, will perform the honorary bell ringing ceremony that will be held 3:50 to 4:00 p.m. ET.  A live webcast will be ava... 
Printer Friendly Version
02/05/16POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
-Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio- -Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure- -US$350 Million Capital Commitment from Deerfield-Led Syndicate- MILTON, Ontario, Feb. 5, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of the business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following a... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.